Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307

OBJECTIVE: To evaluate safety, tolerability, seizure frequency, and regional variations in treatment responses with the AMPA antagonist, perampanel, in a large extension study during up to 3 years of treatment. METHODS: Patients ≥12 years old with partial-onset seizures despite treatment with 1–3 an...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Epilepsia
Glavni autori: Krauss, Gregory L, Perucca, Emilio, Ben-Menachem, Elinor, Kwan, Patrick, Shih, Jerry J, Clément, Jean-François, Wang, Xuefeng, Bagul, Makarand, Gee, Michelle, Zhu, Jin, Squillacote, David
Format: Artigo
Jezik:Inglês
Izdano: BlackWell Publishing Ltd 2014
Teme:
Full-Length Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283992/
https://ncbi.nlm.nih.gov/pubmed/24867391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/epi.12643
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items